SENORES PHARMACEUTICALS L (SENORES) financials

SENORES PHARMACEUTICALS L (SENORES) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]

Market Cap: ₹5,424Cr.
Current Price: ₹1,178
Stock P/E: 292
ROE: 2.78%
ROCE: 4.18%
Book Value: ₹163
Dividend Yield: 0.00%
52W High / Low: ₹1,600/706

In Jun 2026, SENORES PHARMACEUTICALS L (SENORES) reported sales ₹26.99 Cr and net profit ₹1.03 Cr.

Annual TTM: sales ₹124 Cr, net profit ₹19 Cr.

Shareholding: Promoters 45.81% (Sep 2026), FIIs 6.01% (Sep 2026), DIIs 10.85% (Sep 2026), Public 37.32% (Sep 2026), No. of Shareholders 42,642% (Sep 2026).

SENORES quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	9.63	9.59	11.86	16.13	35.33	25.15	36.81	26.99
Expenses	10.97	12.01	14.60	20.98	33.81	29.69	40.29	29.32
Operating Profit	-1.34	-2.42	-2.74	-4.85	1.52	-4.54	-3.48	-2.33
OPM %	-13.91%	-25.23%	-23.10%	-30.07%	4.30%	-18.05%	-9.45%	-8.63%
Other Income	3.09	7.19	9.25	12.08	11.36	13.38	22.19	9.55
Interest	0.68	2.70	2.35	1.76	1.58	1.75	1.89	2.22
Depreciation	0.53	0.75	1.27	1.88	3.65	3.58	4.13	3.61
Profit before tax	0.54	1.32	2.89	3.59	7.65	3.51	12.69	1.39
Tax %	44.44%	18.94%	30.45%	24.79%	15.95%	24.50%	33.18%	25.90%
Net Profit	0.30	1.07	2.01	2.70	6.43	2.65	8.48	1.03
EPS in Rs	0.09	0.23	0.44	0.59	1.40	0.58	1.84	0.22
Raw PDF	—	—	—	—	—	—	—	—

SENORES profit and loss (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	8	14	12	34	39	106	124
Expenses	7	12	14	34	46	125	133
Operating Profit	1	1	-2	-0	-7	-19	-9
OPM %	13%	9%	-14%	-0.2%	-19%	-18%	-7%
Other Income	0	1	7	7	22	66	56
Interest	0	1	2	3	7	7	7
Depreciation	1	1	1	2	3	13	15
Profit before tax	0	1	2	2	5	27	25
Tax %	-110%	18%	38%	60%	28%	26%	—
Net Profit	1	1	1	1	4	20	19
EPS in Rs	2.21	0.69	1.22	0.27	0.80	4.40	4.04
Dividend Payout %	0%	0%	0%	0%	0%	0%	—

SENORES balance sheet (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	4	9	10	31	46	46
Reserves	6	25	29	138	662	704
Borrowings	4	15	61	101	103	85
Other Liabilities	2	7	12	17	23	53
Total Liabilities	15	55	112	286	834	888
Fixed Assets	2	2	8	24	55	102
CWIP	3	3	11	18	34	9
Investments	1	12	8	82	104	154
Other Assets	9	39	84	162	641	623
Total Assets	15	55	112	286	834	888

SENORES cash flows (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-3	-24	-43	-19	-20	-27
Cash from Investing Activity	-4	-10	-5	-57	-163	-19
Cash from Financing Activity	8	34	47	87	533	-3
Net Cash Flow	1	-0	-2	10	349	-49
Free Cash Flow	-6	-25	-52	-39	-70	-62
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	-280%	-2,062%	2,412%	30,117%	260%	118%

SENORES shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	45.77%	45.78%	45.78%	45.80%	45.81%	45.82%	45.82%	45.81%
FIIs	4.25%	4.17%	3.66%	4.28%	3.35%	3.64%	6.62%	6.01%
DIIs	11.77%	9.66%	9.51%	8.62%	9.32%	9.62%	9.77%	10.85%
Public	38.20%	40.39%	41.03%	41.30%	41.54%	40.92%	37.78%	37.32%
No. of Shareholders	49,518	37,653	36,389	34,917	34,401	34,126	36,498	42,642

SENORES key ratios
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	11	226	464	236	243	263
Inventory Days	31	133	194	121	299	65
Days Payable	12	269	273	310	452	210
Cash Conversion Cycle	30	89	385	47	90	118
Working Capital Days	197	102	-566	-656	105	138
ROCE %	—	5%	6%	3%	2%	4%

SENORESUpdated 23 Oct 2026, 11:10

Senores Pharmaceuticals L

SENORESUpdated 23 Oct 2026, 11:10

Market Cap

₹5,424Cr.

Current Price

₹1,178

High / Low

₹1,600/706

Stock P/E

292

Book Value₹163

Dividend Yield0.00%

ROCE4.18%

ROE2.78%

Face Value₹10.0

About

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Dec 2023	8.91	0.67	9.44	2.15	0.46	0.49	59.18	0.2	0.07
Mar 2024	10.61	0.73	8.74	5.18	0.66	5.66	158.83	-3.33	-1.09
Jun 2024	7.48	0.8	8.26	2.45	0.52	0.35	11.43	0.31	0.09
Sep 2024	9.63	0.68	10.97	3.09	0.53	0.54	44.44	0.3	0.09
Dec 2024	9.59	2.7	12.01	7.19	0.75	1.32	18.94	1.07	0.23
Mar 2025	11.86	2.35	14.6	9.25	1.27	2.89	30.45	2.01	0.44
Jun 2025	16.13	1.76	20.98	12.08	1.88	3.59	24.79	2.7	0.59
Sep 2025	35.33	1.58	33.81	11.36	3.65	7.65	15.95	6.43	1.4
Dec 2025	25.15	1.75	29.69	13.38	3.58	3.51	24.5	2.65	0.58
Mar 2026	36.81	1.89	40.29	22.19	4.13	12.69	33.18	8.48	1.84
Jun 2026	26.99	2.22	29.32	9.55	3.61	1.39	25.9	1.03	0.22

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2021	8	0	7	0	1	0	-110	1	2.21
Mar 2022	14	1	12	1	1	1	18	1	0.69
Mar 2023	12	2	14	7	1	2	38	1	1.22
Mar 2024	34	3	34	7	2	2	60	1	0.27
Mar 2025	39	7	46	22	3	5	28	4	0.8
Mar 2026	106	7	125	66	13	27	26	20	4.4
TTM	124	7	133	56	15	25	—	19	4.04

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	45.81%
FIIs	6.01%
DIIs	10.85%
Public	37.32%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2024	45.77%	4.25%	11.77%	38.2%
Mar 2025	45.78%	4.17%	9.66%	40.39%
Jun 2025	45.78%	3.66%	9.51%	41.03%
Sep 2025	45.8%	4.28%	8.62%	41.3%
Dec 2025	45.81%	3.35%	9.32%	41.54%
Mar 2026	45.82%	3.64%	9.62%	40.92%
Jun 2026	45.82%	6.62%	9.77%	37.78%
Sep 2026	45.81%	6.01%	10.85%	37.32%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2021	4	6	4	2	15	2	3	1	9	15
Mar 2022	9	25	15	7	55	2	3	12	39	55
Mar 2023	10	29	61	12	112	8	11	8	84	112
Mar 2024	31	138	101	17	286	24	18	82	162	286
Mar 2025	46	662	103	23	834	55	34	104	641	834
Mar 2026	46	704	85	53	888	102	9	154	623	888

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2021	-3	-4	8	1
Mar 2022	-24	-10	34	0
Mar 2023	-43	-5	47	-2
Mar 2024	-19	-57	87	10
Mar 2025	-20	-163	533	349
Mar 2026	-27	-19	-3	-49

Key ratios

Historical financial ratios

Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	11	226	464	236	243	263
Inventory Days	31	133	194	121	299	65
Days Payable	12	269	273	310	452	210
Cash Conversion Cycle	30	89	385	47	90	118
Working Capital Days	197	102	-566	-656	105	138
ROCE %	—	5%	6%	3%	2%	4%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SENORES PHARMACEUTICALS L (SENORES)?

The reported market capitalisation for SENORES PHARMACEUTICALS L (SENORES) is ₹5,424Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SENORES?

The current price shown for SENORES PHARMACEUTICALS L (SENORES) on Fincrux is ₹1,178 with a 52-week high/low of ₹1,600/706.

What is the P/E ratio of SENORES PHARMACEUTICALS L (SENORES)?

The stock P/E for SENORES PHARMACEUTICALS L (SENORES) is 292 on Fincrux, with ROE at 2.78% and ROCE at 4.18%.

What were SENORES latest quarterly results?

For Jun 2026, SENORES PHARMACEUTICALS L (SENORES) reported sales ₹26.99 Cr and net profit ₹1.03 Cr (figures in ₹ crore unless noted).

What are SENORES annual sales and net profit?

For TTM, SENORES PHARMACEUTICALS L (SENORES) shows sales of ₹124 Cr and net profit of ₹19 Cr on the Fincrux profit & loss statement.

Who owns SENORES PHARMACEUTICALS L (SENORES)?

Latest shareholding for SENORES PHARMACEUTICALS L (SENORES) on Fincrux: Promoters 45.81% (Sep 2026), FIIs 6.01% (Sep 2026), DIIs 10.85% (Sep 2026), Public 37.32% (Sep 2026), No. of Shareholders 42,642% (Sep 2026).

Where can I find SENORES PHARMACEUTICALS L (SENORES) financials?

SENORES PHARMACEUTICALS L (SENORES) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SENORES balance sheet and cash flow?

Yes. The SENORES PHARMACEUTICALS L (SENORES) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 23 October 2026 at 11:10